옵션 체인은 다양한 행사가격과 만기일에 대한 Kura Oncology의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Kura Oncology에 대한 시장 심리를 평가합니다..

Kura Oncology (NASDAQ:KURA) 주식, 옵션 체인

Kura Oncology

Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.

Earnings

Equities

News

Eurozone

Commodities

Markets

Trading Ideas

BIDU

CLCO

KURA

PYXS

QUBT

SNOW

미국 주식은 목요 상승세를 보였으며, 다우존스 지수가  460포인트 이상 상승 마감했다. 다우는 1.06% 상승한 43,870.35로 마감되었고, 나스닥은 0.033% 상승한 18,972.42로 마쳤다. S&amp;P 500 지수도 0.53% 상승한 5,948.71로 마감되었다.

다우존스는 1% 상승 및 나스닥이 소폭 상승: 3분기 실적 발표 후 바이두 주가 하락

Kura Oncology Inc

Kura Sushi Inc

Kura Sushi USA, Inc. - Class A Common Stock

Kura Sushi USA Inc

Kuraray Co Ltd

Shares of SentinelOne Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) were declining ahead of the company's fourth-quarter results due for release on Wednesday, March 12.
The company is likely to report its NNARR (net new annual recurring revenues) slightly higher than consensus estimates and provide "constructive" fiscal 2026 guidance, according to JPMorgan.
The SentinelOne Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5880cc2377f9dd00011b0b74/brian-essex">Analyst Brian Essex</a> reaffirmed an Overweight rating, while reducing the price target from $33 to $27.
The SentinelOne Thesis: While there is some upside to ARR, the most material upside potential is for the company's profitability and free cash flows, Essex said in a note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
While CrowdStrike Holdings Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) outage has added to SentinelOne's pipeline of deals, it has not driven actual results, he added.
The company has invested more in growth initiatives after approaching breakeven in profitability and cash flows, which could trigger an inflection to better NNARR growth in fical 2026, the analyst stated.
"We don't expect the same magnitude of margin expansion we've seen over the past few years, but the company's new CFO seems focused on balancing growth and profitability, and we see potential for operating and FCF margin upside with improvement of operating efficiency across the business in areas that don't necessarily effect growth," Essex wrote.
SentinelOne's stock underperforming peers year to date calls for the reduction in price target, Essex said.
S Price Action: Shares of SentinelOnehad declined by4.48% to $18.96 at the time of publication on Monday.
Read More: <a href="https://www.benzinga.com/content/44065342/why-smart-investors-are-watching-these-3-undervalued-stocks">Why Smart Investors Are Watching These 3 Undervalued Stocks</a>
Photo: Shutterstock

Analyst Color

CRWD

This SentinelOne Analyst Cuts Forecast Ahead Of Q4; Projects Marginal Upside To ARR, Better Profitability

The cryptocurrency community was hit with a stunning twist, when <a href="https://www.benzinga.com/25/03/44208906/trump-declares-us-the-bitcoin-superpower-at-historic-white-house-crypto-summit-with-top-industry-executives">an executive order</a> signed by President Donald Trump dashed the hopes of Ripple and its supporters.
After pouring millions into political contributions to push for XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)'s inclusion in a U.S. sovereign crypto reserve, the company and its co-founders <a href="https://protos.com/ripple-founders-lobbied-for-xrp-reserve-got-sell-only-stockpile-instead/">watched</a> their efforts unravel.
What Happened: Over the weekend, David Sacks, dubbed the "Crypto Czar," shared the signed document on X, revealing that XRP would not be part of any strategic reserve as Trump had once vowed.
Back on March 2, Trump had fueled excitement by pledging to establish a crypto strategic teserve featuring XRP, sparking a 36% price surge for the token within an hour.
Yet, the reality unveiled in the executive order was starkly different. 
Far from elevating XRP to a prized reserve asset, Trump designated it a "Stockpile Asset," meaning the government can only hold or sell it—no purchases allowed. 
The document explicitly states, "the United States Government shall not acquire additional Stockpile Assets other than in connection with criminal or civil asset forfeiture proceedings or in satisfaction of any civil money penalty imposed by any agency without further executive or legislative action."
This sell-only stockpile isn't exclusive to XRP. 
Other popular cryptocurrencies like Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), Cardano (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>), and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)—also name-dropped by Trump in his earlier promise—landed in the same boat. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44217932/crypto-exchange-kraken-sets-sights-on-2025-initial-public-offering">Crypto Exchange Kraken Sets Sights On 2025 Initial Public Offering</a>
Why It Matters: Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) emerged as the golden child, the only digital asset the U.S. government is permitted to actively acquire. Trump's order greenlit a Bitcoin Strategic Reserve, kickstarting it with roughly 200,000 BTC already in federal hands from seizures, though much of that is earmarked for distribution to Bitfinex.
The Treasury and Commerce departments, led by Secretaries Scott Bessent and Howard Lutnick, were tasked with finding budget-friendly ways to bolster Bitcoin holdings.
The fallout for XRP has been swift. 
After its March rally, the token has clung to just 10% of those gains, reflecting the disappointment rippling through its fervent "XRP Army." 
Social media buzzed with frustration, with one X user, Fish Bernoulli, summing it up on March 7: "Created a Bitcoin-only strategic reserve, tasked the treasury to buy more Bitcoin, put existing shitcoins in a stockpile &amp; not buy more."
Adding a layer of confusion, Treasury Secretary Bessent appeared on CNBC the morning of March 10, hinting at a broader vision. "We're starting with Bitcoin, but it's an overall crypto reserve," he said, despite the order's clear Bitcoin-only mandate. 
His comments raised eyebrows, given his role in shaping the acquisition strategy alongside Lutnick, leaving some to wonder if future tweaks might still be in play.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44206614/jpmorgan-questions-viability-of-us-crypto-reserve-cites-issues-with-smaller-tokens">JPMorgan Questions Viability of US Crypto Reserve, Cites Issues With Smaller Tokens</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ADA

$BTC

$ETH

$SOL

$XRP

Why Did Trump's Strategic Crypto Reserve Not Include XRP?

Fox COO Says May Look Into Broadcasting Rights For Major League Baseball

Wells Fargo analyst Alec Brondolo maintains Unity Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) with a Equal-Weight and lowers the price target from $27 to $22.

Price Target

Analyst Ratings

Wells Fargo Maintains Equal-Weight on Unity Software, Lowers Price Target to $22

WIIM

GMAB

Genmab shares are trading lower after the company decided not to exercise its option to receive a worldwide license to develop, manufacture, and commercialize hexabody-cd38.

Benchmark analyst Todd Brooks reiterates Cracker Barrel Old (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRL#NASDAQ">CBRL</a>) from Hold to Hold.

Reiteration

CBRL

Benchmark Reiterates Hold on Cracker Barrel Oldto Hold

President Donald Trump has signed an <a href="https://www.whitehouse.gov/presidential-actions/2025/03/immediate-expansion-of-american-timber-production/">executive order</a> that significantly expands logging on federal lands, removing environmental protections and fast-tracking timber sales. The order directs agencies to ramp up tree cutting across 280 million acres of national forests, bypassing key safeguards under the Endangered Species Act and rolling back regulations that previously limited deforestation. Environmentalists and conservation groups have strongly condemned the move, calling it an unprecedented attack on public lands.
<h2 class="wp-block-heading">Prioritizing Industry Over Conservation</h2>
Trump's order claims that "heavy-handed federal policies" have made the U.S. dependent on foreign timber and that increased logging is necessary for national and economic security. The directive eliminates regulatory hurdles to allow more <a href="https://www.benzinga.com/money/timber-reits">timber production</a> and instructs agencies to streamline permitting for logging projects. It also calls for emergency powers to override environmental protections that prevent the <a href="https://www.benzinga.com/government/regulations/25/01/43137590/microsoft-invests-in-carbon-credits-to-restore-amazon-rainforest-faces-challenges-from-data-center-growth-trumps-fossil-fuel-focus">destruction</a> of old-growth forests, home to countless species.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share today.</a></li>
</ul>
Critics claim that corporate logging interests are the only reason behind this action. The Sierra Club denounced the decision, <a href="https://www.sierraclub.org/press-releases/2025/03/climate-forests-campaign-responds-anti-forests-executive-order">saying</a>, "This executive order will decimate our federal forests. It will use tax dollars to line the pockets of corporate logging interests, undermine environmental laws, and take public forests out of public hands."
<h2 class="wp-block-heading">Environmental Devastation and Increased Wildfire Risks</h2>
Trump has framed the order as a measure to reduce wildfire risks, but many scientists warn that clear-cutting large sections of forests will do the opposite. Chad Hanson, a wildfire scientist at the John Muir Project, criticized the order to <a href="https://www.theguardian.com/us-news/2025/mar/03/trump-national-forest-executive-order">The Guardian</a> as "the most blatant attempt in American history by a president to hand over federal public lands to the logging industry." He added, "Trump falsely claims that more logging will curb wildfires and protect communities, while the overwhelming weight of evidence shows exactly the opposite."
Trending: <a href="https://www.benzinga.com/money/startengine-own">The $1.3 Billion Startup Investment Boom: How This Company's Explosive Growth Is Opening Doors For Everyday Investors With A New $500 Minimum</a>
Hanson explained that logging removes fire-resistant trees and alters the forest microclimate, making conditions hotter, drier, and more prone to fast-moving wildfires. According to him, this was evident in recent <a href="https://www.benzinga.com/news/25/01/43076438/spare-no-expense-says-biden-but-whos-really-footing-the-bill-as-the-los-angeles-wildfire-damage-surpasses-250-billion">Los Angeles wildfires</a>, where extensive logging had actually made fires more severe.
<h2 class="wp-block-heading">Endangered Species and Clean Water at Risk</h2>
Trump's order directs federal agencies to work around the Endangered Species Act, allowing logging to proceed even in areas where it threatens rare and vulnerable wildlife. Conservationists warn that this move could push species like grizzly bears, spotted owls, and wild salmon closer to extinction. The Center for Biological Diversity warned in a <a href="https://biologicaldiversity.org/w/news/press-releases/trumps-logging-order-unleashes-chainsaws-on-americas-national-forests-2025-03-03/">statement</a> that the order "will unleash the chainsaws and bulldozers on our federal forests. Clear-cutting these beautiful places will increase fire risk, drive species to extinction, pollute our rivers and streams, and destroy world-class recreation sites."
In addition to harming wildlife, the destruction of forests will affect water supplies for millions of Americans. Mature forests filter and store clean water, and their removal could result in widespread pollution and depletion of vital resources.
See Also: <a href="https://www.benzinga.com/money/overplay">Mark Cuban Backs This Innovative Startup That Turns Videos into Games&nbsp; &#8212; Claim Your Share Now</a>
<h2 class="wp-block-heading">Industry Takeover of Public Lands</h2>
Trump's pro-industry stance is further evident in his appointment of Tom Schultz, a former executive at lumber producer Idaho Forest Group as the new chief of the U.S. Forest Service. Schultz will now oversee 154 national forests and 193 million acres of land, roughly the size of Texas. His appointment follows <a href="https://www.benzinga.com/news/25/03/44066466/when-the-bill-comes-it-will-be-monumental-experts-warn-trumps-mass-federal-firings-could-leave-a-tremendous-financial-burden">mass layoffs</a> at the Forest Service, including 2,000 workers, many of whom were responsible for wildfire prevention and environmental oversight.
The decision to install a logging executive at the helm of the nation's forests has sparked outrage. Anna Medema from the Sierra Club criticized the move, <a href="https://www.sierraclub.org/press-releases/2025/02/sierra-club-statement-nomination-tom-schultz-run-us-forest-service">saying</a>, "Naming a corporate lobbyist to run the agency tasked with overseeing the last old growth left in the U.S. makes it clear that the Trump administration's goal isn't to preserve our national forests, but to sell them off to billionaires and corporate polluters."
<h2 class="wp-block-heading">Public Backlash and the Fight to Save Forests</h2>
Environmental groups, scientists, and conservationists are vowing to fight back, warning that this decision will have devastating consequences for wildlife, climate, and future generations. As Randi Spivak of the Center for Biological Diversity put it: "This is a particularly horrific move by Trump to loot our public lands by handing the keys to big business."
Read Next:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>

'Horrific Move To Loot Our Public Lands'—Trump Signs Executive Order To Clear-Cut 280M Acres Of National Forests

Deep-pocketed investors have adopted a bearish approach towards Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in OXY usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Occidental Petroleum. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 10% leaning bullish and 60% bearish. Among these notable options, 5 are puts, totaling $488,519, and 5 are calls, amounting to $179,680.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $50.0 to $65.0 for Occidental Petroleum over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Occidental Petroleum's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Occidental Petroleum's whale activity within a strike price range from $50.0 to $65.0 in the last 30 days. 
<h3>Occidental Petroleum Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741616137_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>OXY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/04/25</td>
<td>$7.4</td>
<td>$7.0</td>
<td>$7.26</td>
<td>$54.00</td>
<td>$131.0K</td>
<td>2</td>
<td align="right">411</td>
</tr>
<tr>
<td>OXY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/04/25</td>
<td>$6.6</td>
<td>$6.05</td>
<td>$6.34</td>
<td>$53.00</td>
<td>$114.6K</td>
<td>32</td>
<td align="right">181</td>
</tr>
<tr>
<td>OXY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/04/25</td>
<td>$7.3</td>
<td>$6.75</td>
<td>$7.03</td>
<td>$54.00</td>
<td>$112.2K</td>
<td>2</td>
<td align="right">26</td>
</tr>
<tr>
<td>OXY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.05</td>
<td>$3.0</td>
<td>$3.0</td>
<td>$50.00</td>
<td>$105.0K</td>
<td>5.6K</td>
<td align="right">361</td>
</tr>
<tr>
<td>OXY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$5.6</td>
<td>$5.5</td>
<td>$5.5</td>
<td>$55.00</td>
<td>$44.0K</td>
<td>443</td>
<td align="right">1</td>
</tr>
</tbody>
</table>

<h3>About Occidental Petroleum</h3>
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2023, the company reported net proved reserves of nearly 4 billion barrels of oil equivalent. Net production averaged 1,327 thousand barrels of oil equivalent per day in 2024 at a ratio of roughly 50% oil and natural gas liquids and 50% natural gas.
After a thorough review of the options trading surrounding Occidental Petroleum, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Occidental Petroleum's Current Market Status</h3>
<ul>
<li>With a volume of 1,555,887, the price of OXY is down -0.18% at $46.91. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 57 days.</li>
</ul>
<h3>Expert Opinions on Occidental Petroleum</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $58.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Stephens &amp; Co. lowers its rating to Overweight with a new price target of $71. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Neutral rating for Occidental Petroleum, targeting a price of $56. 
&#x2A; An analyst from Raymond James has revised its rating downward to Outperform, adjusting the price target to $64. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Equal-Weight rating on Occidental Petroleum with a target price of $52. 
&#x2A; An analyst from Piper Sandler has decided to maintain their Neutral rating on Occidental Petroleum, which currently sits at a price target of $50. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Occidental Petroleum, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Smart Money Is Betting Big In OXY Options

Investors with a lot of money to spend have taken a bearish stance on Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ZS, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 12 uncommon options trades for Zscaler.
This isn't normal.
The overall sentiment of these big-money traders is split between 25% bullish and 50%, bearish.
Out of all of the special options we uncovered, 8 are puts, for a total amount of $520,725, and 4 are calls, for a total amount of $145,190.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $180.0 to $230.0 for Zscaler over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Zscaler's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Zscaler's whale activity within a strike price range from $180.0 to $230.0 in the last 30 days. 
<h3>Zscaler 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741616132_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$41.5</td>
<td>$39.35</td>
<td>$40.65</td>
<td>$230.00</td>
<td>$81.3K</td>
<td align="right">7</td>
<td align="right">20</td>
</tr>
<tr>
<td>ZS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$34.8</td>
<td>$34.3</td>
<td>$34.8</td>
<td>$220.00</td>
<td>$69.6K</td>
<td align="right">158</td>
<td align="right">20</td>
</tr>
<tr>
<td>ZS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$35.05</td>
<td>$34.0</td>
<td>$34.65</td>
<td>$220.00</td>
<td>$69.3K</td>
<td align="right">158</td>
<td align="right">40</td>
</tr>
<tr>
<td>ZS</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$35.0</td>
<td>$33.95</td>
<td>$34.5</td>
<td>$220.00</td>
<td>$69.0K</td>
<td align="right">158</td>
<td align="right">60</td>
</tr>
<tr>
<td>ZS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$35.55</td>
<td>$35.05</td>
<td>$35.05</td>
<td>$220.00</td>
<td>$59.5K</td>
<td align="right">158</td>
<td align="right">78</td>
</tr>
</tbody>
</table>

<h3>About Zscaler</h3>
Zscaler is a software-as-a-service, or SaaS, firm focusing on providing cloud-native cybersecurity solutions to primarily enterprise customers. Zscaler's offerings can be broadly partitioned into Zscaler Internet Access, which provides secure access to external applications, and Zscaler Private Access, which provides secure access to internal applications. The firm is headquartered in San Jose, California, and went public in 2018.
In light of the recent options history for Zscaler, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Zscaler's Current Market Status</h3>
<ul>
<li>Trading volume stands at 309,697, with ZS's price down by -3.54%, positioned at $201.37.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 80 days.</li>
</ul>
<h3>Expert Opinions on Zscaler</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $238.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Zscaler, targeting a price of $250. 
&#x2A; Maintaining their stance, an analyst from Rosenblatt continues to hold a Neutral rating for Zscaler, targeting a price of $190. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Zscaler with a target price of $250. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Zscaler, targeting a price of $250. 
&#x2A; An analyst from Baird has decided to maintain their Outperform rating on Zscaler, which currently sits at a price target of $250. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Zscaler options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Zscaler's Options: A Look at What the Big Money is Thinking

Financial giants have made a conspicuous bearish move on CrowdStrike Holdings. Our analysis of options history for CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) revealed 25 unusual trades.
Delving into the details, we found 36% of traders were bullish, while 52% showed bearish tendencies. Out of all the trades we spotted, 20 were puts, with a value of $1,164,949, and 5 were calls, valued at $270,674.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $250.0 to $425.0 for CrowdStrike Holdings during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for CrowdStrike Holdings options trades today is 558.42 with a total volume of 296.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for CrowdStrike Holdings's big money trades within a strike price range of $250.0 to $425.0 over the last 30 days.
<h3>CrowdStrike Holdings 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741616127_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRWD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$81.65</td>
<td>$79.0</td>
<td>$79.31</td>
<td>$400.00</td>
<td>$269.6K</td>
<td>1.3K</td>
<td align="right">34</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/04/25</td>
<td>$9.3</td>
<td>$9.0</td>
<td>$9.3</td>
<td>$340.00</td>
<td>$93.0K</td>
<td>17</td>
<td align="right">101</td>
</tr>
<tr>
<td>CRWD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$92.65</td>
<td>$89.95</td>
<td>$90.74</td>
<td>$400.00</td>
<td>$90.7K</td>
<td>73</td>
<td align="right">10</td>
</tr>
<tr>
<td>CRWD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$88.7</td>
<td>$87.3</td>
<td>$88.7</td>
<td>$400.00</td>
<td>$88.7K</td>
<td>530</td>
<td align="right">10</td>
</tr>
<tr>
<td>CRWD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/14/25</td>
<td>$58.75</td>
<td>$54.95</td>
<td>$57.95</td>
<td>$375.00</td>
<td>$86.9K</td>
<td>184</td>
<td align="right">15</td>
</tr>
</tbody>
</table>

<h3>About CrowdStrike Holdings</h3>
CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.
<h3>Current Position of CrowdStrike Holdings</h3>
<ul>
<li>With a trading volume of 879,467, the price of CRWD is down by -5.82%, reaching $314.09.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 85 days from now.</li>
</ul>
<h3>What The Experts Say On CrowdStrike Holdings</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $422.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Needham lowers its rating to Buy with a new price target of $420. 
&#x2A; An analyst from Susquehanna persists with their Positive rating on CrowdStrike Holdings, maintaining a target price of $425. 
&#x2A; In a cautious move, an analyst from Raymond James downgraded its rating to Outperform, setting a price target of $390. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for CrowdStrike Holdings, targeting a price of $450. 
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on CrowdStrike Holdings, maintaining a target price of $429. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for CrowdStrike Holdings with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Behind the Scenes of CrowdStrike Holdings's Latest Options Trends

McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) has outperformed the market over the past 5 years by 21.31% on an annualized basis producing an average annual return of 37.34%. Currently, McKesson has a market capitalization of $81.20 billion. 
Buying $1000 In MCK: If an investor had bought $1000 of MCK stock 5 years ago, it would be worth $5,223.62 today based on a price of $647.88 for MCK at the time of writing.
<h3>McKesson's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741616114_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning McKesson Stock In The Last 5 Years

Guidance

Genmab Says Johnson & Johnson Decision Regarding HexaBody-CD38 Does Not Impact 2025 Financial Guidance

The year began on a strong note, with the market climbing over 3% in January amid optimism fueled by Trump's presidency and his market-focused policies. In February, that bullish sentiment persisted until tariffs became the central issue.
Initially, Trump set a deadline of February 1 for imposing 25% tariffs on Mexico and Canada, though he later reached an alternative agreement focused on curbing the fentanyl crisis. The market largely brushed off these developments and continued its upward trend. However, the mood shifted on February 13 when Trump and Commerce Secretary Lutnick announced a broader set of reciprocal tariffs.
The market maintained its momentum for a short period, reaching an all-time high of 6,144 on February 19. But on February 21, a disappointing University of Michigan consumer confidence report sparked fears of inflation and stagflation, leading to a market collapse and a shift toward a bearish sentiment. Despite this, the S&amp;P 500 has only dipped by 0.44%, a much smaller decline than some media outlets have suggested.
This modest drop appears bullish to me. Tariffs represent a significant policy obstacle, and once their impact is absorbed, the market is likely to rebound. Furthermore, anticipated tax cuts later in the year could serve as a strong catalyst for further gains.
In parallel, the Trump administration has succeeded in reducing the 10-year yield from 4.80% in January to 4.20% currently. Although concerns about economic growth remain, this lower yield is expected to provide additional support, working in tandem with tax cuts to boost the market.
Amid the prevailing fear, I see excellent buying opportunities. The reaction to the tariffs seems exaggerated, and I remain very bullish, forecasting that the S&amp;P 500 will reach 7,000 by year's end.

Market Summary

Broad U.S. Equity ETFs

Econ #s

ETFs

S&P 500 Will Reach 7,000 By Year-End

EPR Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPR#NYSE">EPR</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $53.0, a high estimate of $58.00, and a low estimate of $50.00. Witnessing a positive shift, the current average has risen by 8.16% from the previous average price target of $49.00.
<img src="https://www.benzinga.com/files/images/story/2025/1741616070_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive EPR Props. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Kilichowski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$52.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$58.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Simon Yarmak</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$52.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Brad Heffern</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to EPR Props. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of EPR Props compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of EPR Props's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of EPR Props's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EPR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on EPR Props analyst ratings.</a>
<h2>Get to Know EPR Props Better</h2>
EPR Properties is a real estate investment trust that focuses on underwriting experiential property investments on key industry and property cash flow criteria, and the credit metrics of tenants and customers. The company invests in two property segments: Experiential, including theaters, family entertainment centers, ski resorts, and other attractions; and Education, including early childhood education centers and private school properties. The Company's business is focused on Experiential real estate. The majority of revenue comes from the Experiential sector.
<h3>Breaking Down EPR Props's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: EPR Props's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 2.58%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: EPR Props's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -8.8%, the company may face hurdles in effective cost management.
Return on Equity (ROE): EPR Props's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.61% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): EPR Props's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.26%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 1.32, EPR Props adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down EPR Props: 4 Analysts Share Their Views

In the latest quarter, 7 analysts provided ratings for Equity Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQR#NYSE">EQR</a>), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $77.71, with a high estimate of $83.00 and a low estimate of $74.00. This current average has increased by 0.05% from the previous average price target of $77.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1741616062_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Equity Residential among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$78.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$79.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$76.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>James Feldman</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$75.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Richard Hightower</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$79.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Vikram Malhorta</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$74.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Richard Hightower</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$83.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Equity Residential. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Equity Residential compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Equity Residential's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Equity Residential's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EQR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Equity Residential analyst ratings.</a>
<h2>All You Need to Know About Equity Residential</h2>
Equity Residential owns a portfolio of 311 apartment communities with around 84,000 units and is developing two additional properties with 655 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.
<h3>Equity Residential: A Financial Overview</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Equity Residential's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 5.4%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Real Estate sector.
Net Margin: Equity Residential's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 54.61%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Equity Residential's ROE excels beyond industry benchmarks, reaching 3.83%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Equity Residential's ROA excels beyond industry benchmarks, reaching 2.01%. This signifies efficient management of assets and strong financial health.
Debt Management: Equity Residential's debt-to-equity ratio is below the industry average at 0.76, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Equity Residential Through 7 Analysts

<ul>
<li>Johnson &amp; Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38</li>
<li>Genmab will not pursue further clinical development of HexaBody-CD38</li>
<li>Data validates clinical potential of the HexaBody platform</li>
<li>Genmab to host a conference call today at 5:00 PM CET / 4:00 PM GMT / 12:00 PM EDT</li>
</ul>
COPENHAGEN, Denmark; March 10, 2025 – <a href="https://www.globenewswire.com/Tracker?data=2jy2jmHgLka6YSWX2AWjGnlxlSmdCYL8XdVOJE-3BVZVFYHLPZGygTz_h51hGpxCsleRY51478TNlNtDnnAt5Q==">Genmab A/S</a> (NASDAQ:<a href="https://www.benzinga.com/stock/GMAB#NASDAQ">GMAB</a>) announced today that Johnson &amp; Johnson (J&amp;J) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 (GEN3014). While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab's rigorous portfolio prioritization, Genmab will not pursue further clinical development&nbsp;of HexaBody-CD38.

Biotech

Contracts

General

Genmab Announces Johnson & Johnson Has Decided That It Will Not Exercise Its Option To Receive A Worldwide License To Develop, Manufacture And Commercialize HexaBody-CD38; Genmab Will Not Pursue Further Clinical Development

In the preceding three months, 12 analysts have released ratings for CME Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $256.58, with a high estimate of $287.00 and a low estimate of $212.00. This current average has increased by 4.22% from the previous average price target of $246.18. 
<img src="https://www.benzinga.com/files/images/story/2025/1741616044_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of CME Group among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick O'Shaughnessy</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$287.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$263.00</td>
<td>$256.00</td>
</tr>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$257.00</td>
<td>$256.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$269.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$269.00</td>
<td>$258.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Underweight</td>
<td>$212.00</td>
<td>$209.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$263.00</td>
<td>$257.00</td>
</tr>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$256.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$258.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$235.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Christopher Allen</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$250.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$260.00</td>
<td>$237.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CME Group. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CME Group compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for CME Group's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of CME Group's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CME/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CME Group analyst ratings.</a>
<h2>About CME Group</h2>
Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and in 2002 completed its IPO. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&amp;P Dow Jones Indices, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&amp;P futures contracts. Through CME's acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization.
<h3>CME Group: Delving into Financials</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Positive Revenue Trend: Examining CME Group's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.98% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 56.62%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): CME Group's ROE stands out, surpassing industry averages. With an impressive ROE of 3.16%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.63%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: CME Group's debt-to-equity ratio is below the industry average at 0.13, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On CME Group Through 12 Analysts

Benchmark analyst Daniel Kurnos reiterates Magnite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>) with a Buy and maintains $25 price target.

MGNI

Benchmark Reiterates Buy on Magnite, Maintains $25 Price Target

FOXA

Fox COO Says "May Partner With Other Streamers Who Are In The Market To Offer A Bundle" For Co's New Streaming Service

Fox COO Says Co Brought About 125 New Advertisers To Fox News Since The Election; Across Entertainment And Sports Cancellations Are At Historic Lows; Subscriber Expectations For New Streaming Service Is At Mid Single Digit Millions Over Next 3 To 5 Years

Press Releases

Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit

Kura Oncology to Host Virtual Investor Event on December 9, 2024

Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting

Management

Kura Oncology Announces Senior Executive Promotions

Health Care

Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs

Comments

Kura Oncology

Kura Oncology (KURA) 옵션

Kura Oncology (NASDAQ:KURA) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌